ACC video: EVEREST II surmounts its two-year feat

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Click to play
ACC Video: Saibil Kar, MD
Everest II Co-investigator
Cedars Sinai Medical Center
Los Angeles, CA
NEW ORLEANS—Co-investigator Saibil Kar, MD, of Cedars-Sinai Medical Center in Los Angeles, explained the two-year follow-up results of the EVEREST II randomized controlled trial, which compared the results observed at 12 months to determine the durability of outcomes through 24 months for the device and control groups using the MitraClip device (Abbott) or surgical repair for patients with mitral regurgitation. The late breaking clinical trial was presented April 4 at the American College of Cardiology (ACC) Scientific Sessions.